These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19771324)

  • 1. Molecule of the Month. Denosumab.
    Drug News Perspect; 2009; 22(6):356. PubMed ID: 19771324
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
    Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
    J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab for treatment of postmenopausal osteoporosis.
    Chitre M; Shechter D; Grauer A
    Am J Health Syst Pharm; 2011 Aug; 68(15):1409-18. PubMed ID: 21785030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab.
    Rizzoli R; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2010 Aug; 9(8):591-2. PubMed ID: 20671758
    [No Abstract]   [Full Text] [Related]  

  • 5. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
    Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
    N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporosis drug licensed for women with high fracture risk.
    Traynor K
    Am J Health Syst Pharm; 2010 Jul; 67(13):1046. PubMed ID: 20554585
    [No Abstract]   [Full Text] [Related]  

  • 7. Denosumab update.
    Lewiecki EM
    Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C
    Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing options for the treatment of osteoporosis.
    Khosla S
    N Engl J Med; 2009 Aug; 361(8):818-20. PubMed ID: 19671654
    [No Abstract]   [Full Text] [Related]  

  • 11. Denosumab--a new option in the treatment of osteoporosis.
    Franek E
    Endokrynol Pol; 2011; 62(1):79-83. PubMed ID: 21365584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab for the treatment of postmenopausal osteoporosis.
    Lewiecki EM
    Womens Health (Lond); 2009 Jan; 5(1):15-22. PubMed ID: 19274891
    [No Abstract]   [Full Text] [Related]  

  • 14. Denosumab: new horizons in the treatment of osteoporosis.
    Wilton JM
    Nurs Womens Health; 2011; 15(3):249-52. PubMed ID: 21672176
    [No Abstract]   [Full Text] [Related]  

  • 15. Denosumab and bisphosphonates: different mechanisms of action and effects.
    Baron R; Ferrari S; Russell RG
    Bone; 2011 Apr; 48(4):677-92. PubMed ID: 21145999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe?
    Tankó LB
    Curr Opin Investig Drugs; 2007 Oct; 8(10):830-5. PubMed ID: 17907059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A step in the journey of denosumab from bone-targeted therapy to seed- and soil-targeted therapy.
    Vignot S; Khayat D
    J Clin Oncol; 2009 Apr; 27(10):1534-6. PubMed ID: 19237628
    [No Abstract]   [Full Text] [Related]  

  • 19. Denosumab.
    Dubois EA; Rissmann R; Cohen AF
    Br J Clin Pharmacol; 2011 Jun; 71(6):804-6. PubMed ID: 21434974
    [No Abstract]   [Full Text] [Related]  

  • 20. Denosumab for the treatment of osteoporosis.
    Iqbal J; Sun L; Zaidi M
    Curr Osteoporos Rep; 2010 Dec; 8(4):163-7. PubMed ID: 20857349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.